Skip to main content

Psoriatic arthritis

Sleep asleep
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many. Psoriatic arthritis is associated with a number of sleep problems, including…
Best of
The last day was jammed with important reports and research including the late breaking abstracts.    What imaging modality is best in GCA? Dutch study: n=42 ?GCA got all three of USS, PET/CT, MRI…
pills-384846_640%20%281%29.jpg
A few things we know about opioids: use is common; it’s not efficacious in the treatment of spondyloarthritis; and, there is an opioid epidemic and its users are stigmatized.  Opioid use can weigh…
RT @RichardPAConway: Curtis et al. Primary non-adherence to csDMARDs and b/tsDMARDs in RA/PsA/SpA. Medicare and commeric

Richard Conway RichardPAConway

3 weeks 1 day ago
Curtis et al. Primary non-adherence to csDMARDs and b/tsDMARDs in RA/PsA/SpA. Medicare and commerically-insured patients. 20-44%! of new prescriptions not filled by 6 months. Higher for csDMARDs than b/tsDMARDs @RheumNow #ACR22 Abstr#2199 https://t.co/Pwg6GKu7Gg https://t.co/wPF0pu1UDa
RT @RHEUMarampa: Pain in #psoriaticarthritis might not be all inflammatory..
In this study presented by Dr F Sunzini:
ð
3 weeks 1 day ago
Pain in #psoriaticarthritis might not be all inflammatory.. In this study presented by Dr F Sunzini: 👉PsA pts w/⬆️FM scores had⬆️functional brain connectivity bet mid-post IC & thalamus, phgyrus & PFC ..so consider nociplastic pain too & adjust mgt #ACR22 @RheumNow ABST#2256 https://t.co/suCAvx0pD5
RT @doctorRBC: BE OPTIMAL Study - Bimekizumab (IL-17A and IL-17F inhibitor) for treatment of PsA.
Similar ACR 50 (~50%)

Robert B Chao, MD doctorRBC

3 weeks 1 day ago
BE OPTIMAL Study - Bimekizumab (IL-17A and IL-17F inhibitor) for treatment of PsA. Similar ACR 50 (~50%) response rates of Bimekizumab, adalimumab, and placebo (switched to BKZ at wk 16). ~60% PASI100 in BKZ #ACRBest Abs#L02 @RheumNow #ACR22 https://t.co/W2B2kyju9F
RT @RichardPAConway: Ritchlin et al. Bimekizumab in bDMARD naive PsA. 52 week results. Not surprisingly, week 16 outcome

Richard Conway RichardPAConway

3 weeks 1 day ago
Ritchlin et al. Bimekizumab in bDMARD naive PsA. 52 week results. Not surprisingly, week 16 outcomes sustained. No joint difference to ADA, skin slightly better @RheumNow #ACR22 Abstr#L02 https://t.co/RjCV8Hb3HR https://t.co/a0NQFyFZlt
×